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Problem: Levetiracetam (LEV) is a new antiepileptic drug shown to be effective for the treatment of partial seizures in pivotal
clinical trials. We investigated the long-term efficacy and tolerability of LEV as add-on therapy, regardless of seizure type,
especially in persons who would not be eligible for clinical trials due to factors such as mental retardation and concomitant
psychiatric disorders.
Methods: Ninety-eight patients participated and were followed for 1 year. Demographic data, seizure frequency, and side effects
were recorded at baseline and during the 1-year follow-up. The first 35 patients were given LEV at a starting dose of 500 mg
b.i.d. with weekly increments of 1000 mg (fast titration). The other patients were given LEV with a starting dose of 250 mg b.i.d.
with weekly increments of 250 mg (slow titration).
Results: Fourteen patients were completely seizure free after titration to effective dose and 57 were responders with >50%
seizure reduction for the first year. In the group with generalized seizures, 1 out of 19 became seizure free, but 8 patients had
>50% decrease. Average dose at 1 year was 1900 mg (±900). Seventeen of 38 discontinuations were due to adverse effects and
21 were due to lack of efficacy. With fast titration, 15 out of 35 (43%) experienced tiredness during the first 12 weeks, and with
slower titration 20 of 63 (32%) experienced tiredness. The difference was not statistically significant.
Four out of the five patients who discontinued due to behavioral adverse events (mainly irritability) previously had behavioral
problems and/or mental retardation. One patient discontinued due to psychosis.
Conclusions: Levetiracetam appears to be well tolerated in patients with severe epilepsy and shows efficacy in a long-term
follow-up. Behavioral adverse events were noted in a small number of patients and occurred mainly in patients who had a history
of behavioral disturbance or were mentally retarded. These data from an open population are consistent with the findings of
clinical trials.
© 2002 BEA Trading Ltd. Published by Elsevier Science Ltd. All rights reserved.
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INTRODUCTION
Levetiracetam (LEV) is a new antiepileptic drug
(AED) recently approved for use in the USA and EU
countries. It has been available since April 2000 in the
USA and available for compassionate use in Sweden
since August 2000 and as a commercial drug since
January 2001. Registration was based on clinical tri-
als and safety data from 1422 patients with epilepsy.
A total of 3000 people have been treated with LEV
before registration.
So far there have been no published postmarketing
prospective reports concerning the long-term clinical
efficacy or safety of LEV in a clinical setting. This,
therefore, is, to our knowledge, the first report of the
results of long-term treatment of consecutive patients
with LEV who suffer from various types of seizures
and syndromes.
METHODS
Design
This is a single-center, prospective add-on open-label
treatment study.
Patient eligibility criteria were maintenance of a
seizure diary by the patient or a caretaker for the
3 months before enrollment, and continued seizures
that were refractory to all previous treatments. There
was no restriction to specific seizure type or epilepsy
syndrome. Ninety-eight patients were enrolled in the
study to receive LEV as adjunctive therapy.
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Patients were stratified into those with epilepsy
of focal origin, those with generalized symptomatic
epilepsy (as Lennox–Gastaut Syndrome), and those
with generalized idiopathic epilepsies (absence
epilepsy, juvenile myoclonic epilepsy, and included
in this group was two patients, one with Baltic my-
oclonic epilepsy (BME) and one with Lafora body
disease (LBD)).
LEV dose
The first 35 patients were given LEV according to
labeling at a starting dose of 500 mg twice daily
and increased with weekly increments of 1000 to
1000 mg twice daily. If efficacy was not satisfactory,
the dose was then increased to 1500 mg twice daily.
The rest of the patients, from patient 36 to 98, began
with a starting dose of 250 mg day−1 and increased
by 250 mg every week to 500 mg twice daily. If
seizure control was not satisfactory and there were no
side effects, then the dose was increased by 500 mg
weekly to 2000 mg day−1 and then if necessary to
3000 mg day−1.
Follow-up
Patients came for a clinic visit approximately ev-
ery third month for 1 year. Seizure frequency and
side effects were recorded using patient diaries. The
3-month baseline seizure frequency was determined
by reviewing the preexisting patient diaries. Changes
in concomitant medication were done only if a patient
reported side effects of concomitant AEDs before
starting LEV (such as peripheral field deficits due
to vigabatrin or weight gain due to valproate). No
new therapies were added during the entire follow-up
period.
Efficacy variables
Efficacy was measured as seizure freedom, 75–99%
seizure reduction, 50–74% seizure reduction, 25–49%
seizure reduction, no response up to 25% seizure re-
duction, and increased seizures. The number of pa-
tients who became seizure free after dose titration was
recorded. To evaluate a possible tolerance effect, pa-
tients who achieved a 90–100% seizure reduction and
then experienced a loss of the original efficacy were
registered.
Side effects
Side effects were recorded and divided into side effects
causing withdrawal, those occurring during the first
12 weeks of therapy and those occurring or continuing
later than 12 weeks after treatment started.
Statistical analysis
Parametric data are expressed as mean and standard
deviation or range. Nonparametric data are expressed
as median and range. Proportions are expressed as per-
centages. The Kruskal–Wallis test was used for mul-
tiple comparisons in efficacy between seizure types.
Correlations were tested with Spearman’s rank cor-
relation, while comparisons in adverse events were
tested with Chi-square. No corrections for multiple
comparisons were made. A Kaplan–Meier survival
curve was also generated using the Statview software.
RESULTS
Patient characteristics
A total of 98 patients participated in the study.
Seventy-nine had focal-onset epilepsy, 12 had symp-
tomatic generalized epilepsy, 4 had generalized
idiopathic epilepsy with absences and generalized
tonic–clonic seizures, 1 had LBD, 1 had BME, and 1
had juvenile myoclonic epilepsy. The average age was
38.9 (range:12–68 years) and the average life-span
with epilepsy was 69% (±0.25%). The average base-
line seizure frequency was 14 seizures per month but
the range varied from 1 to 110 seizures per month,
(SD = 21.5). Fifty-one of the 98 patients were males.
Ten patients previously had serious psychiatric dis-
turbances, 22 were mentally handicapped, and 33 pa-
tients received active vagus nerve stimulation (VNS),
although a total of 44 had tried VNS. Sixteen had pre-
viously undergone resective epilepsy surgery. In other
words, most of the patients in this study were refrac-
tory to other conventional treatments. Twenty-four
patients were taking one other concomitant AED, 45
were taking two, 22 were taking three, 5 were taking
four other AEDs and 1 took five concomitant AEDs.
The AEDs that were taken by 10 or more patients
were: carbamazepine (n = 52), topiramate (25), val-
proic acid (22), phenytoin (20), lamotrigin (19), vi-
gabatrin (17), clobazam (16), and phenobarbital (10).
One patient received LEV as monotherapy from the
start of the study as she had stopped the other AEDs
because of lack of efficacy.
Efficacy
Patients with focal-onset epilepsy
Seventy-nine patients were included in the partial-onset
seizure group. All but three had two or more seizures
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Table 1: Reduction in seizure frequency.
Epilepsy type Localized Generalized idiopathic Generalized symptomatic
Total n = 79 n = 7 n = 12
Seizure free 13 (16%) 1 (14%) 0 (0%)
75–99% reduction 26 (33%) 2 (29%) 2 (17%)
50–74% reduction 10 (13%) 2 (29%) 1 (8%)
25–49% reduction 1 (1%) 0 (0%) 1 (8%)
0–24% reduction 27 (34%) 2 (29%) 7 (68%)
Increased seizures 2 (3%) 0 (0%) 1 (8%)
The number and percentage of the patients with different types of epilepsy syndromes divided according to the change in seizure
frequency compared to baseline observed over a 6-month period after the introduction of LEV.
per month (median: 5 per month). Seizures types
consisted of simple partial, complex partial, and/or
secondarily generalized seizures. During the year of
treatment, a total of 49 patients had a >50% seizure
reduction, 27 (34%) did not experience any signifi-
cant seizure reduction, and 2 (3%) actually reported
an increase in seizures (see Table 1). One (1%) pa-
tient experienced a 25–50% seizure reduction, 10
(13%) had a 50–74% seizure reduction, 26 (33%)
had a 75–99% reduction in seizures, and 13 (16%)
were seizure free after titration to effective dose. The
average dose for the patients that continued to take
LEV throughout the study was 1900 mg day−1 (range:
250–4000 mg day−1). For the patients who were
seizure free, the average dose was 1500 mg day−1
(range: 1000–3000). Fifteen patients were seizure
free from the start of therapy but four patients (not
included in the final seizure-free group count) had a
relapse after 1–3 months. Only one of these four pa-
tients had previously reduced their concomitant AED.
Twenty-eight withdrew from therapy with LEV after
a median of 23 weeks (range 2–59).
Patients with symptomatic generalized epilepsy
Twelve patients suffered from symptomatic general-
ized epilepsy. In this group, one patient experienced
an increase in seizures, seven had no response, and
three were responders with >75% seizure reduction
(Table 1). Seven stopped LEV after an average of 2
months of treatment.
Patients with idiopathic generalized seizures
This group was comprised of seven patients. Four
had refractory absence seizures with generalized
tonic–clonic seizures. One patient had BME. One
had juvenile myoclonic epilepsy and one had LBD.
The patient with juvenile myoclonic epilepsy and
one with absence epilepsy did not respond at all to
LEV. The patients with BME and LBD experienced a
>50% reduction in seizure frequency and myoclonic
jerks. One patient with absence epilepsy had a 30%
decrease in seizures, one had a 90% seizure reduc-
tion, and one was seizure free for 1 year on a dose of
1000 mg day−1.
Correlations between efficacy and other variables
Using the Kruskal–Wallis test, no significant differ-
ences were found between seizures types (simple par-
tial, complex partial, secondary generalized seizures,
absences, myoclonia, primary generalized seizures or
atonic seizures) and efficacy (P = 0.179). Using the
Spearman’s rank correlation, there were no significant
correlation between the number of AEDs taken be-
fore adding LEV and efficacy (r = 0.2; P = 0.12), or
the duration of epilepsy (percent of life with epilepsy)
and response to treatment (r = 0.2; P = 0.1). Pa-
tients with VNS responded in the same way as those
without (P = 0.2).
Of the 14 patients who became seizure free, no one
had more than 11 seizures per month before adding
LEV. By the end of the first year, 61% (n = 60) were
still taking LEV while 39% (n = 38) had dropped out
(see Fig. 1).
Adverse events
Forty-two patients reported having side effects while
taking LEV. Tiredness was the primary side effect re-
ported. Of the 35 patients started on fast titration of
LEV (500 mg b.i.d. for the first week and 1000 b.i.d.
for the second week), 15 patients complained of ini-
tial tiredness. This did not resolve in three after more
than 12 weeks of treatment. In the 63 patients with
slow titration (250 mg day−1 for the first week with
an increase of 250 mg week−1 up to 2000 mg day−1),
20 complained of tiredness initially and 10 out of the
59 still treated still had symptoms after 12 weeks of
treatment. The frequency of tiredness, any other ad-
verse event, or discontinuation of LEV, did not differ
significantly between the groups. Other side effects
were irritation (n = 5 initially and 7 after 12 weeks).
Other side effects were pruritis (n = 3), increased
seizures (n = 3), and psychosis (n = 1). Nineteen
patients stopped treatment due to side effects without
or in combination with the lack of effect. Another 17
134 E. Ben-Menachem & E. Gilland
Fig. 1: Kaplan–Meier survival curve for 1-year treatment
with LEV showing the percent of patients still being treated.
patients stopped treatment solely due to lack of effect.
In total, 38 patients discontinued LEV (see Table 2).
No deaths occurred in this cohort of patients. There
have been no pregnancies reported so far.
Behavioral adverse events, mainly irritability, were
reported by five during the first 12 weeks of treatment
and by seven after the first 12 weeks of treatment.
This led to discontinuation of the drug in four of these
patients. Three stopped by 12 weeks and one stopped
only later on. The type of irritation in the four patients
who discontinued could rather be called aggression.
When the drug was stopped aggression and irritation
resolved immediately. All but one of the patients
who exhibited aggression and who were subsequently
discontinued previously had behavioral problems
and mental retardation. One patient discontinued the
drug due to psychosis. He, previously had behavioral
disturbances with bouts of psychosis, was mentally
retarded and his epilepsy was very refractory. He did
not experience any seizure reduction with LEV.
Table 2: Number of patients who experienced adverse events after the introduction of LEV.
Side effect Early (<12 weeks), n = 98 Late (>12 weeks), n = 88 Reason for withdrawal, n = 98
Irritated 5 (5%) 7 (8%) 4 (4%)
Tiredness 36 (37%) 13 (15%) 10 (10%)
Rash and itch 0 (0%) 3 (3%) 1 (1%)
Gastrointestinal disturbance 0 (0%) 0 (0%) 0 (0%)
Psychosis 0 (0%) 1 (1%) 1 (1%)
Paresis 1 (1%) 0 (0%) 1 (1%)
Increased seizures 2 (2%) 1 (1%) 3 (3%)
Data is presented as number (percentage).
DISCUSSION
Refractory epilepsy is a difficult condition to treat and
most patients, regardless of syndrome, usually try nu-
merous drugs and interventions in an attempt to reduce
seizure frequency and ultimately become seizure free.
The patients in this study all had intractable epilepsy
and were interested in trying LEV when it became
available, as very few would have met all inclusion
criteria for participation in a clinical trial, due to fac-
tors such as mental retardation, number of concomi-
tant AEDs, and previous psychiatric illness. Thus, it
is encouraging to find that efficacy was very good in
45% (>75% seizure reduction) in this difficult to treat
group of patients. This compares very favorable with
the efficacy profiles of other new AEDs1.
Long-term follow-up from the clinical trials of LEV,
mainly concerning patients with focal-onset seizures
support the results of our study. Retention rates were
60% after 1 year and 32% after 5 years2. The respon-
der rate for >50% seizure reduction in their study was
39%. There were 13% who were seizure free for the
last 6 months of treatment and 8% who were seizure
free at the last year.
The side effect profile of LEV seems to be, at least
in our study, limited to fatigue or tiredness, and some
reports of irritation and aggression. The tiredness de-
scribed by our patients was primarily one of lack of
energy, but not necessarily sleepiness. Slower titra-
tion than is recommended in the registration instruc-
tions did not significantly lower the complaint rate.
Still our impression is that slow titration will enable
the physician and patient to evaluate the effect and
side effects of the drug in a more controlled setting.
From the pooled data from the randomized control
trials (RCT), somnolence was the most frequent re-
ported side effect with 14% of patients complaining
and 12% complaining about asthenia3. In our study,
the two side effects were grouped into the single term
of tiredness because it was not possible to always
differentiate between the two problems as they were
often intertwined. Irritation was also an initial com-
plaint, but only in five patients and in five after 12
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weeks, of which three developed this side effect after
12 weeks of therapy. Concerning the side effect of ir-
ritation, usually it was a relative who reported that the
patient could become more easily angry or stressed.
In the pooled placebo-controlled trial data3, irritation
was not reported as a major adverse event. Perhaps
this discrepancy occurred because our patients were
not people who could be included in a clinical trial
because they often had behavioral and psychiatric dis-
orders as well as mental handicaps. Interestingly, the
behavioral adverse events were not related to seizure
reduction so ‘forced normalization’ did not seem to
be an important factor in this study.
The shortcomings of this study are that (1) it is a
single center study, but at least all the patients could be
meticulously accounted for; (2) it is not a randomized
placebo-controlled study but it is very hard to follow
refractory patients in a blinded fashion for long-term
trials and is probably not ethical to treat with placebo
for such extended periods of time.
In the placebo-controlled studies and long-term
follow-up studies2–6, doses were predetermined by
protocol and most patients remained on the dose des-
ignated by the study if it was tolerable. In our study,
we could titrate slowly to response, and, therefore,
found that many of our patients achieved good effi-
cacy at lower doses than expected. In fact, the patients
who became seizure free often did so on lower doses
than those who did not (average dose 1500 mg com-
pared to average dose 1900 mg for nonseizure-free
patients). The interesting feature of this drug was
that most of the seizure-free patients became seizure
free early on during titration, even from the very
first tablet. Most often this result was sustained but
four of the patients spontaneously developed seizures
again after 1–4 months. This is often observed when
adding on AED therapies, but there did not seem to
be evidence of tolerance in the majority of patients
in this study. Once a level of efficacy was achieved,
it seemed to be sustained in most patients over the
entire study period as evidenced by the survival rates.
All patients, regardless of seizure type, were in-
cluded in this investigation. Although most were
patients with focal-onset epilepsy with simple partial,
complex partial, and secondarily generalized seizure
types, 19 of 98 patients had either generalized symp-
tomatic or generalized idiopathic epilepsy syndromes.
In the generalized symptomatic group, only three
were truly responders. The others had either marginal
effects or none at all. Seizure types in this group were
atonic seizures, generalized tonic or tonic–clonic
seizures or atypical absences. The patients in this
group had previously tried multiple therapies before
so it is impossible to determine if LEV would be ef-
fective in symptomatic generalized epilepsy judging
by the result of this small sample. The few patients
in the idiopathic generalized epilepsy group tended
to do better. Patient with unusual seizure types as
seen in BME and LBD were included and both re-
sponded very favorably with reduction of seizures
and stimulus sensitive myoclonia. Piracetam, which
has similar characteristics to LEV and was developed
from the same parent compound, is a highly effec-
tive drug for myoclonia. Perhaps LEV and piracetam
share the same mechanistic properties in controlling
myoclonus. The full mechanism of action of LEV is,
however, so far undisclosed.
In conclusion, LEV seems to be a broad spectrum
AED with surprisingly few side effects. Its efficacy
in focal-onset seizures is impressive. Efficacy with
this drug in other epilepsy syndromes remains promis-
ing, but new ongoing placebo-controlled studies will
further clarify its efficacy. Tolerability seems to be
good in all patients no matter seizure type or epilepsy
syndrome.
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